- Home
- AMTB vs PHVS Comparison
AMTB vs PHVS Comparison
Compare AMTB & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMTB
- PHVS
- Stock Information
- Founded
- AMTB 1979
- PHVS 2015
- Country
- AMTB United States
- PHVS Netherlands
- Employees
- AMTB N/A
- PHVS N/A
- Industry
- AMTB Major Banks
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- AMTB Finance
- PHVS Health Care
- Exchange
- AMTB Nasdaq
- PHVS Nasdaq
- Market Cap
- AMTB 727.1M
- PHVS 1.0B
- IPO Year
- AMTB N/A
- PHVS 2021
- Fundamental
- Price
- AMTB $21.84
- PHVS $20.35
- Analyst Decision
- AMTB Hold
- PHVS Buy
- Analyst Count
- AMTB 6
- PHVS 5
- Target Price
- AMTB $25.40
- PHVS $33.60
- AVG Volume (30 Days)
- AMTB 74.5K
- PHVS 120.7K
- Earning Date
- AMTB 10-17-2024
- PHVS 10-31-2024
- Dividend Yield
- AMTB 1.64%
- PHVS N/A
- EPS Growth
- AMTB N/A
- PHVS N/A
- EPS
- AMTB 0.61
- PHVS N/A
- Revenue
- AMTB $327,309,000.00
- PHVS N/A
- Revenue This Year
- AMTB N/A
- PHVS N/A
- Revenue Next Year
- AMTB $5.12
- PHVS N/A
- P/E Ratio
- AMTB $35.90
- PHVS N/A
- Revenue Growth
- AMTB 8.52
- PHVS N/A
- 52 Week Low
- AMTB $16.63
- PHVS $15.00
- 52 Week High
- AMTB $27.00
- PHVS $33.00
- Technical
- Relative Strength Index (RSI)
- AMTB 55.74
- PHVS 58.11
- Support Level
- AMTB $19.92
- PHVS $20.29
- Resistance Level
- AMTB $22.17
- PHVS $21.22
- Average True Range (ATR)
- AMTB 0.63
- PHVS 1.27
- MACD
- AMTB 0.11
- PHVS 0.20
- Stochastic Oscillator
- AMTB 80.00
- PHVS 73.79
About AMTB Amerant Bancorp Inc.
Amerant Bancorp Inc is a bank holding company. Through its bank, it provides individuals and businesses deposit, credit, investment, wealth management, and fiduciary services, both in the United States and to select international customers. The bank also provides banking services through traditional channels, such as banking centers and ATMs, as well as via secure websites, mobile devices, and telephones.
About PHVS Pharvaris N.V.
Pharvaris NV is a clinical-stage company. It is focused on the discovery and development and commercialization of therapies for rare diseases with significant unmet need, initially focused on angioedema and other bradykinin-mediated diseases. The company's activities are considered to be one segment which comprises the discovery, development and commercialization of oral bradykinin-B2-receptor antagonists .